All In Biotech

NDA 019853 · Valeant Pharms Intl

Cuprimine

Penicillamine · Oral · Antirheumatic Agent

Novel

Last checked: Nov 20, 2026Latest source record: Oct 26, 2004 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1970

Dec 4, 1970

Approved uses

1

Original approval plus efficacy supplements

Registered trials

12

6 Phase 3, 1 recruiting

FAERS reports

914

706 serious, 91 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity.

What it is approved for

From the label in effect Jan 26, 2026.

INDICATIONS CUPRIMINE is indicated in the treatment of Wilson’s disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that CUPRIMINE is not of value in ankylosing spondylitis. Wilson’s Disease Wilson’s disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal-recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology. Two types of patients require treatment for Wilson’s disease: (1) the symptomatic, and (2) the asymptomatic in whom it can be assumed the disease will develop in the future if the patient is not treated. The diagnosis, if suspected on the basis of family or individual history or physical examination, can be confirmed if the plasma copper-protein ceruloplasmin** is less than 20 mg/dL and either a quantitative determination in a liver biopsy specimen shows an abnormally high concentration of copper (greater than 250 mcg/g dry weight) or Kayser-Fleischer rings are present. Treatment has two objectives: (1) to minimize dietary intake of copper; (2) to promote excretion and complex formation (i.e., detoxification) of excess tissue copper. The first objective is attained by a daily diet that contains...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 4, 1970 Original approval · Type 1 - New Molecular Entity
2 products under this application
  • CUPRIMINE · PENICILLAMINE 125MG · CAPSULE, ORAL · Discontinued
  • CUPRIMINE · PENICILLAMINE 250MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Penicillamine" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity181
  • drug ineffective175
  • arthralgia148
  • joint swelling143
  • inflammation111
  • nausea94
  • off label use94
  • diarrhoea89
  • headache83
  • hypersensitivity81
  • drug intolerance79
  • anaphylactic reaction77

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200447
200531
200621
200722
200816
200925
201023
201125
201214
201315
201416
201517
201639
201777
201882
201990
2020117
202168
202248
202342
202429
202536
202614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cuprimine (Penicillamine)

2024 spending

$1.9M

Beneficiaries

n/a

57 claims

Per beneficiary

n/a

$252.67 per unit

View as table
YearSpending
2020$5,088,859
2021$3,404,409
2022$2,531,210
2023$2,095,299
2024$1,944,581

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 338 on PubMed

Sponsor: Valeant Pharms Intl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.